Dr. Oludare Odumosu

Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a developer of cannabinoid-based medicines, will conduct FDA Phase 2 and Phase 3 clinical trials for its HOPE-1 treatment of Autism Spectrum Disorder (ASD). Cantheon Capital LLC agreed to provide an initial $8.6 million in funding to Zelira to...

Zelira Therapeutics Ltd’s (OTCQB: ZLDAF) (ASX:ZLD) insomnia medication Zenivol has achieved formal approval from German regulatory authority BfArM to launch in the German medical cannabis market. According to the company, Zenivol is the world's first and only clinically validated,...

Zelira Therapeutics (OTC: ZLDAF), a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, is about to begin a first-ever clinical trial of its own proprietary pain formula for the treatment of diabetic nerve pain...